Trial Profile
Clinical Trials Insight: 700027120
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2007
Price :
$35
*
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Nventa Biopharmaceuticals Corporation
- 24 Sep 2007 New trial record.